Effects of sildenafil on pulmonary hypertension and exercise tolerance in severe cystic fibrosis-related lung disease

Pediatric Pulmonology

Volumn 41, Issue 4, 2006, Pages 383-385

  Montgomery, Gregory S ^a,c   Sagel, Scott D ^b   Taylor, Amy L ^b   Abman, Steven H ^b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

6 min walk test; Cystic fibrosis; Echocardiogram; Exercise; Phosphodiesterase inhibitor; Pulmonary hypertension; Sildenafil

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ADULT; ARTICLE; CASE REPORT; CYSTIC FIBROSIS; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FUNCTION TEST; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HYPOXIA; LUNG DISEASE; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIX MINUTE WALK TEST; THORAX PAIN;

ADULT; CYSTIC FIBROSIS; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; MALE; PIPERAZINES; VASODILATOR AGENTS;

EID: 33645311511     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20393     Document Type: Article

References (15)

1. Goldring RM, Fishman AP, Turino GM, Cohen HI, Denning CR, Andersen DH. Pulmonary hypertension and cor pulmonale in cystic fibrosis of the pancreas. J Pediatr 1964;65:501-524.
2. Fraser KL, Tullis E, Sasson Z, Hyland RH, Thornley KS, Hanly PJ. Pulmonary hypertension and cardiac function in adult cystic fibrosis. Chest 1999;115:1321-1328.
3. Bright-Thomas RJ, Webb AK. The heart in cystic fibrosis. J R Soc Med [Suppl] 2002;95:2-10.
4. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83:13-20.
5. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000;84:4.
6. Carroll WD, Dhillon R. Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 2003;88:827-828.
7. Michelakis ED, Tymchak W, Noga M, Webster L, Wu X-C, Lien D, Wang S-H, Modry D, Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-2069.
8. Ryland D, Reid L. The pulmonary circulation in cystic fibrosis. Thorax 1975;30:285-292.
9. Moskowitz WB, Gewitz MH, Heyman S, Ruddy RM, Scanlin TF. Cardiac involvement in cystic fibrosis: early noninvasive detection and vasodilator therapy. Pediatr Pharmacol (New York) 1985;5:139-148.
10. Davidson A, Bossuyt A, Dab I. Acute effects of oxygen, nifedipine, and diltiazem in patients with cystic fibrosis and mild pulmonary hypertension. Pediatr Pulmonol 1989;6:53-59.
11. Kelminson LL, Cotton EK, Vogel JH. The reversibility of pulmonary hypertension in patients with cystic fibrosis. Observations on the effects of tolazoline hydrochloride. Pediatrics 1967;39:24-35.
12. Geggel RL, Dozor AJ, Fyler DC, Reid LM. Effect of vasodilators at rest and during exercise in young adults with cystic fibrosis and chronic cor pulmonale. Am Rev Respir Dis 1985;131:531-536.
13. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424-428.
14. Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med 2004;169:227-234.
15. Dormer RL, Harris CM, Clark Z, Pereira MM, Doull U, Norez C, Becq F, McPherson MA. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005;60:55-59.